ALZN

Alzamend Neuro Inc

Add to Watchlist

Advanced Chart

2.530

+0.04(1.606%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.620

Open

2.500

VWAP

2.49

Vol

396.07K

Mkt Cap

8.70M

Low

2.420

Amount

987.33K

EV/EBITDA(TTM)

Total Shares

7.38M

2.94M

EV/OCF(TTM)

P/S(TTM)

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q4

FY2026Q3

FY2026Q2

-0.780

-91.77%

-3.320

+94.15%

-3.080

-14.44%

Estimates Revision

The market is revising No Change the revenue expectations for Alzamend Neuro, Inc. (ALZN) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -14.24%.

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-14.24%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ALZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALZN is 6.90 USD with a low forecast of 6.90 USD and a high forecast of 6.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 2.530

Low

6.90

Averages

6.90

High

6.90

Current: 2.530

Low

6.90

Averages

6.90

High

6.90

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$32 → $20

2025-03-17

Reason

Ascendiant Capital

Edward Woo

Price Target

$32 → $20

2025-03-17

Maintains

Strong Buy

Reason

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$35 → $32

2024-12-16

Reason

Ascendiant Capital

Edward Woo

Price Target

$35 → $32

2024-12-16

Maintains

Strong Buy

Reason

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$50 → $35

2024-11-11

Reason

Ascendiant Capital

Edward Woo

Price Target

$50 → $35

2024-11-11

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Alzamend Neuro Inc (ALZN.O) is -0.43, compared to its 5-year average forward P/E of -21.01. For a more detailed relative valuation and DCF analysis to assess Alzamend Neuro Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-21.01

Current PE

-0.43

Overvalued PE

32.36

Undervalued PE

-74.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.07

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

7.98

Undervalued EV/EBITDA

-22.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00